UroGen Pharma Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $188.7M+108.8% YoYTTM through 30 Jun 2026
Net Income -$97.6MTTM through 30 Jun 2026
Free Cash Flow -$159.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 88.7% |
| EBITDA Margin | -35.2% |
| Operating Margin | -113.7% |
| Net Margin | -51.7% |
Returns
73.7%ROE
-76.6%ROA
Balance Sheet Health
Debt / Equity-2.35x
Current Ratio3.80x
Net Debt$127.7M
Cash & Equivalents$79.1M
Quality Metrics
Altman Z-Score-1.57
Piotroski F-Score3 / 9
FCF Margin-84.3%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $109.8M
Diluted EPSFY2025: $-3.19
Dividend
No dividend
Capital Allocation
R&D Spend$61.3M
Capex Intensity0.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| JELMYTO | $94M | +7.0% | View detailsGuidance for full-year 2026 net product sales for JELMYTO is expected to be in the range of $97 million to $101 million. |
| ZUSDURI | $15.8M | View detailsPermanent J-Code became effective January 1, 2026, streamlining reimbursement and supporting broader patient access. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.